s20098 has been researched along with Infarction, Middle Cerebral Artery in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chumboatong, W; Govitrapong, P; Khamchai, S; Tocharus, C; Tocharus, J | 2 |
| Cao, Y; Long, J; Wang, F; Wang, Y | 1 |
3 other study(ies) available for s20098 and Infarction, Middle Cerebral Artery
| Article | Year |
|---|---|
Agomelatine Exerts an Anti-inflammatory Effect by Inhibiting Microglial Activation Through TLR4/NLRP3 Pathway in pMCAO Rats.
Topics: Acetamides; Animals; Anti-Inflammatory Agents; Brain Ischemia; Infarction, Middle Cerebral Artery; Male; Microglia; Naphthalenes; NF-kappa B; NLR Family, Pyrin Domain-Containing 3 Protein; Rats; Rats, Sprague-Dawley; Rats, Wistar; Toll-Like Receptor 4 | 2022 |
Agomelatine protects against permanent cerebral ischaemia via the Nrf2-HO-1 pathway.
Topics: Acetamides; Animals; Brain; Heme Oxygenase (Decyclizing); Infarction, Middle Cerebral Artery; Male; Melatonin; Neurons; Neuroprotective Agents; NF-E2-Related Factor 2; Rats, Wistar; Signal Transduction | 2020 |
Agomelatine prevents macrophage infiltration and brain endothelial cell damage in a stroke mouse model.
Topics: Acetamides; Animals; Blood-Brain Barrier; Brain; Cell Hypoxia; Cell Movement; Chemokine CCL2; Claudin-5; Disease Models, Animal; Down-Regulation; Endothelial Cells; Infarction, Middle Cerebral Artery; Macrophages; Mice; Permeability; Stroke; Tight Junction Proteins | 2021 |